RB1 aberrations predict outcomes of immune checkpoint inhibitor combination therapy in NSCLC

INTRODUCTION: Immune checkpoint inhibitors (ICI) have changed the treatment of non-small cell lung cancer (NSCLC). Furthermore, compared with monotherapy, ICI combination therapy had better efficacy and partly different mechanism. Therefore, we aim to investigate and improve biomarkers specialized f...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qian, Yu, Tao, Ke, Zi-Hao, Wang, Fu-Feng, Yin, Jia-Ni, Shao, Yang, Lu, Kai-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334286/
https://www.ncbi.nlm.nih.gov/pubmed/37441425
http://dx.doi.org/10.3389/fonc.2023.1172728

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334286/
https://www.ncbi.nlm.nih.gov/pubmed/37441425
http://dx.doi.org/10.3389/fonc.2023.1172728

Ejemplares similares